Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22


Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators.

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.


Patterns of alcohol consumption and myocardial infarction risk: observations from 52 countries in the INTERHEART case-control study.

Leong DP, Smyth A, Teo KK, McKee M, Rangarajan S, Pais P, Liu L, Anand SS, Yusuf S; INTERHEART Investigators.

Circulation. 2014 Jul 29;130(5):390-8. doi: 10.1161/CIRCULATIONAHA.113.007627. Epub 2014 Jun 13.


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators.

N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.


The effect of chromosome 9p21 variants on cardiovascular disease may be modified by dietary intake: evidence from a case/control and a prospective study.

Do R, Xie C, Zhang X, Männistö S, Harald K, Islam S, Bailey SD, Rangarajan S, McQueen MJ, Diaz R, Lisheng L, Wang X, Silander K, Peltonen L, Yusuf S, Salomaa V, Engert JC, Anand SS; INTERHEART investigators.

PLoS Med. 2011 Oct;8(10):e1001106. doi: 10.1371/journal.pmed.1001106. Epub 2011 Oct 11.


Apixaban with antiplatelet therapy after acute coronary syndrome.

Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators.

N Engl J Med. 2011 Aug 25;365(8):699-708. doi: 10.1056/NEJMoa1105819. Epub 2011 Jul 24.


Irbesartan in patients with atrial fibrillation.

ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.

N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816.


Dabigatran versus warfarin in patients with atrial fibrillation.

Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators.

N Engl J Med. 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.


Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S.

N Engl J Med. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoa0901301. Epub 2009 Mar 31.


[Effect of pulseless ventricular tachycardia on sympathetic activity].

Szili-Török T, Földesi C, Stegeman B, Török Z, Sitkei E, Farkas T, Rudas L.

Orv Hetil. 2007 Jun 24;148(25):1185-8. Hungarian.


Renal function and outcomes in acute coronary syndrome: impact of clopidogrel.

Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, Mehta SR, Yusuf S; CURE Trial Investigators.

Eur J Cardiovasc Prev Rehabil. 2007 Apr;14(2):312-8.


Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events.

Active Steering Committee; ACTIVE Investigators, Connolly S, Yusuf S, Budaj A, Camm J, Chrolavicius S, Commerford PJ, Flather M, Fox KA, Hart R, Hohnloser S, Joyner C, Pfeffer M, Anand I, Arthur H, Avezum A, Bethala-Sithya M, Blumenthal M, Ceremuzynski L, De Caterina R, Diaz R, Flaker G, Frangin G, Franzosi MG, Gaudin C, Golitsyn S, Goldhaber S, Granger C, Halon D, Hermosillo A, Hunt D, Jansky P, Karatzas N, Keltai M, Lanas F, Lau CP, Le Heuzey JY, Lewis BS, Morais J, Morillo C, Oto A, Paolasso E, Peters RJ, Pfisterer M, Piegas L, Pipillis T, Proste C, Sitkei E, Swedberg K, Synhorst D, Talajic M, Trégou V, Valentin V, van Mieghem W, Weintraub W, Varigos J.

Am Heart J. 2006 Jun;151(6):1187-93.


Surgical removal from the descending aorta of a floating thrombus caused by blunt chest trauma.

Lukács L, Lengyel M, Sitkei E, Abermann L.

Cardiovasc Surg. 1996 Dec;4(6):846-7.


[Thrombolysis by tissue plasminogen activator in acute myocardial infarct].

Keltai M, Dékány P, Németh J, Palik I, Sitkei E, Szente A, Arvay A.

Orv Hetil. 1991 Sep 15;132(37):2019-24. Review. Hungarian.


[Pacemaker implantation in atrioventricular block, a manifestation of Kearns-Sayre syndrome].

Temesvári A, Sitkei E, Szatmári A, Bendig L, Keltai M.

Orv Hetil. 1987 Jul 26;128(30):1563-4. Hungarian. No abstract available.


[Digitalis sensitivity in chronic obstructive lung disease].

Perger L, Sitkei E, Matos L, Nagy K.

Orv Hetil. 1984 Jan 1;125(1):17-20. Hungarian. No abstract available.


After group home living--what alternative? Results of a two year mobility followup study.

Sitkei EG.

Ment Retard. 1980 Feb;18(1):9-13. No abstract available.


Study of a new frontier in community services: residential facilities for the developmentally disabled.

Oconnor G, Sitkei EG.

Ment Retard. 1975 Aug;13(4):35-9. No abstract available.


A methodological report on household psychometric screening for retardation.

Watts CA, Sitkei EG, Meyers CE.

Community Ment Health J. 1969 Feb;5(1):88-94. doi: 10.1007/BF01419806.


Attitudes toward special education and the handicapped in two community groups.

Meyers CE, Sitkei EG, Watts CA.

Am J Ment Defic. 1966 Jul;71(1):78-84. No abstract available.


Supplemental Content

Loading ...
Support Center